- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars
Patients who research medical information online are likely to be more concerned about switching from originator products to biosimilars, according to the study.
A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.
Patients who do online searching for medical information about biosimilars are liable to have exacerbated concerns about switching to biosimilars, according to the study, which examined patient attitudes toward these agents. The findings also indicated that women are more likely to have concerns about switching from originator drugs to biosimilars.
Among the findings:
- There was a positive correlation between adverse events experiences from the originator and adverse events anticipated from the biosimilar (P < .001.
- There was a positive association between perceptions of originator safety and the expectation that biosimilars are unsafe (P <.001).
- There was a significant negative association between the perceived effectiveness of the current originator and a preference for a biosimilar medicine (P <.001).
To read more about the findings, visit The Center for Biosimilars.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
5 Key Drug Approvals and CRLs in 2024
December 27th 2024In 2024, multiple drugs received complete response letters (CRLs), sometimes unrelated to the safety and efficacy of the drug, but patients with schizophrenia gained the first new treatment with a new mechanism of action in decades.
Read More
From Approval to Practice: Addressing the Hurdles in Biosimilar Integration
December 12th 2024Recent discussions at an Institute for Value-Based Medicine event highlighted the significant potential of biosimilars in reshaping the health care landscape, despite facing considerable barriers to adoption.
Read More
